News from Decision Resources, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 20, 2013, 11:00 ET The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


Aug 19, 2013, 10:00 ET Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinson's Disease on Their Largest Commercial Plan

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that up to 60...


Aug 14, 2013, 08:00 ET The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...


Aug 08, 2013, 08:00 ET China's Type 2 Diabetes Market Will Grow To $3.5 Billion In 2017

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2...


Aug 05, 2013, 09:00 ET Indonesia's Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Indonesia's...


Aug 01, 2013, 10:30 ET Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceutical's Brintellix Has Blockbuster Potential

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that...


Aug 01, 2013, 09:00 ET Despite Diagnostic Inroads, the Hepatitis B Virus Patient Populations in Brazil, Mexico and Argentina Remain Undertreated

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that nearly 60...


Jul 31, 2013, 09:00 ET MCOs' Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 68 percent of...


Jul 30, 2013, 10:00 ET The Launch of Three New Parkinson's Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of...


Jul 29, 2013, 10:34 ET Novartis's Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function

  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on...


Jul 25, 2013, 09:00 ET The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As Time-Tested Therapies Lose Ground to New Entrants

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market...


Jul 22, 2013, 09:00 ET The Financial Impact of Obesity in Brazil and Mexico's Healthcare Systems is Driving Partial Coverage of Obesity Drugs in Formularies at the State, Municipal and Hospital Levels

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while...


Jul 17, 2013, 09:31 ET For Pulmonary Hypertension, Surveyed Pulmonologists Indicate that a Reduced Risk of Morbidity/Mortality is One of the Key Factors Driving Their Prescribing

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...


Jul 16, 2013, 10:00 ET Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals' Opana ER Have Not Increased PCPs' Comfort When Prescribing These Products for Chronic Pain

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the...


Jul 15, 2013, 09:00 ET In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of...


Jul 10, 2013, 09:00 ET Physicians and MCOs Believe Accountable Care Organizations Could Generate Savings of at Least 12 Percent in Asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both managed care...


Jul 09, 2013, 10:00 ET Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...


Jul 08, 2013, 09:00 ET For the Treatment of First-Line Metastatic Pancreatic Cancer, Thought-Leaders are Optimistic About the Potential Efficacy Advantages of Two Emerging Agents Over Currently Available Therapies

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the...


Jul 02, 2013, 10:00 ET In Brazil, Mexico and Argentina, High Out-of-Pocket Costs For DPP-IV Inhibitors and GLP-1 Analogues Greatly Limit Prescribing of These Drugs in the Public Setting for the Treatment of Type 2 Diabetes

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...


Jul 01, 2013, 09:00 ET For Persistent Asthma, Surveyed Pulmonologists Indicate That a Reduced Rate of Exacerbations is One of the Greatest Unmet Needs

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...